EVMN Evommune, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 2044725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-84.4%
TTM EPS YoY131.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-331.4%
ROA-62.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets9.7%
Debt / equity0.00x
Current ratio8.52x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $10.00M | $0 | $3.00M | $0 |
| R&D expense | $24.55M | $26.41M | $17.32M | $20.40M | $19.64M | $19.64M | $14.36M | $17.83M |
| SG&A expense | $8.78M | $8.48M | $6.63M | $9.31M | $3.69M | $3.36M | $3.67M | $3.62M |
| Operating income | -$33.33M | -$34.90M | -$23.95M | -$29.72M | -$13.33M | -$22.99M | -$15.03M | -$21.45M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$30.88M | -$32.25M | -$21.67M | -$28.27M | -$12.47M | -$13.56M | -$14.56M | -$20.73M |
| EBITDA | -$33.13M | -$34.70M | -$23.85M | -$29.62M | -$13.23M | -$22.79M | -$14.83M | -$21.88M |
| EPS (basic) | -0.85 | -0.89 | -0.64 | — | -8.07 | -8.80 | -9.48 | — |
| EPS (diluted) | -0.85 | -0.89 | -0.64 | — | -8.07 | -8.80 | -9.48 | — |
| Weighted avg. shares (diluted) | 36.33M | 36.14M | 33.67M | — | 1.55M | 1.54M | 1.53M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $47.57M | $60.03M | $48.32M | $44.06M | $26.82M | $61.84M | $5.70M | $16.46M |
| Short-term investments | $121.07M | $140.76M | $163.15M | $105.14M | $49.24M | — | — | $55.78M |
| Current assets | $174.56M | $204.25M | $215.85M | $153.48M | $81.94M | — | — | $73.99M |
| PP&E, net | $1.63M | $1.65M | $1.64M | $994,000 | $970,000 | — | — | $1.33M |
| Total assets | $278.30M | $301.95M | $322.45M | $224.95M | $84.54M | — | — | $76.06M |
| Current liabilities | $20.48M | $17.49M | $10.60M | $17.91M | $10.42M | — | — | $27.98M |
| Total liabilities | $26.93M | $24.36M | $17.90M | $19.38M | $10.68M | — | — | $28.52M |
| Shareholders' equity | $251.37M | $277.59M | $304.56M | $205.57M | -$183.14M | -$171.23M | -$158.24M | -$144.24M |
| Shares outstanding | 36.38M | 36.28M | 36.02M | 31.52M | 1.55M | — | — | 1.55M |
| Cash flow statement | ||||||||
| Operating cash flow | -$25.88M | -$20.32M | -$27.50M | -$16.70M | -$9.63M | -$26.21M | -$23.90M | -$18.51M |
| Capital expenditure | $233,000 | $183,000 | $83,000 | $104,000 | $131,000 | $0 | $0 | $0 |
| Free cash flow | -$26.11M | -$20.50M | -$27.59M | -$16.80M | -$9.77M | -$26.21M | -$23.90M | -$18.51M |
| Investing cash flow | $13.32M | $31.29M | -$85.36M | -$122.90M | -$23.91M | $18.00M | $13.50M | -$33.08M |
| Financing cash flow | $94,000 | $532,000 | $117.11M | $156.85M | -$274,000 | $64.34M | -$152,000 | $49.70M |
| Depreciation & amortization | $200,000 | $200,000 | $100,000 | $100,000 | $100,000 | $200,000 | $200,000 | -$427,000 |
| Stock-based compensation | $4.42M | $4.60M | $3.45M | $4.20M | $561,000 | $557,000 | $544,000 | $494,000 |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.